Related Experiment Video
Updated: Jul 9, 2025

Autologous Blood Injection to Model Spontaneous Intracerebral Hemorrhage in Mice
Published on: August 24, 2011
Alternating hemiplegia of childhood
Piriyankan Ananthavarathan1, Salwa Kamourieh1
1Department of Neurology, Headache and Facial Pain Group, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom.
Insights
Alternating hemiplegia of childhood (AHC) is a severe neurodevelopmental disorder. Mutations in the ATP1A3 gene are implicated, and flunarizine is the preferred treatment for preventing attacks.
Area of Science:
- Pediatric Neurology
- Neurogenetics
- Rare Diseases
Background:
- Alternating hemiplegia of childhood (AHC) presents with recurrent hemiplegic episodes and severe neurodevelopmental impairments.
- Associated symptoms include dystonia, nystagmus, dysautonomia, developmental delay, and epilepsy.
- Diagnosis relies on clinical history and Aicardi criteria.
Conclusions:
- AHC is a complex neurodevelopmental disorder with a genetic basis in ATP1A3.
- Effective management involves symptomatic treatment, trigger avoidance, and specific pharmacotherapies like flunarizine.
Abstract:
Alternating hemiplegia of childhood (AHC) is characterized by recurrent episodes of hemiplegia which may alternate sides between attacks. The condition is associated with severe neurodevelopmental disorder presenting in early infancy, and may encompass a wide range of other paroxysmal manifestations (e.g., dystonia, nystagmus, dysautonomia) and pervasive neurological disabilities (e.g., developmental delay, learning disabilities, choreoathetosis, and ataxia). Epileptic seizures are particularly common among patients with AHC. Diagnosis is usually based on history and clinical grounds using the Aicardi criteria. Mutations in the ATP1A3 gene are implicated in the disease pathology of the condition, as well as several other neurodevelopmental disorders, suggesting AHC forms part of a spectrum of overlapping clinical syndromes rather than a distinct clinical entity per se. Management of patients with AHC includes the rapid induction of sleep during paroxysmal attacks and the avoidance of identified triggers. Pharmacotherapeutic treatments have a role in managing epileptic seizures, as well as in the prevention of paroxysmal attacks wherein flunarizine remains the treatment of choice.
More Related Videos
08:26Event-related Potentials During Target-response Tasks to Study Cognitive Processes of Upper Limb Use in Children with Unilateral Cerebral Palsy
Published on: January 11, 2016
06:04Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE
Published on: August 16, 2024
Related Concept Videos
Cerebral Hemispheres
Lateralization